Navigation Links
Cell death researchers identify new Achilles heel in acute myeloid leukemia
Date:1/17/2012

Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

The research team at the institute was led by Dr Stefan Glaser, from the institute's Cancer and Haematology division, and Professor Andreas Strasser, joint head of the institute's Molecular Genetics of Cancer Division, working in collaboration with scientists from the Australian Centre for Blood Diseases and St. Vincent's Institute of Medical Research in Melbourne, as well as Austrian and American researchers. The research is published in this week's edition of the journal Genes & Development.

AML is the most common type of acute leukaemia (rapidly-developing cancers of immature blood cells) in Australia. Some forms of AML occur in children, while other forms are more prevalent in adults over the age of 60. Patients are normally treated with chemotherapy, but even for the least severe forms of AML, the disease returns after chemotherapy in around one-third of cases. Of patients with the most severe forms of AML, fewer than one in six will survive for five years after diagnosis.

The research team determined that treatments that remove the protein Mcl-1 from AML cells can rapidly kill these aggressive cancer cells. Mcl-1 is a so-called 'pro-survival' protein, because it can make cells long-lived. Mcl-1 is part of the 'Bcl-2 family' of pro-survival proteins, many of which are known to be important controllers of cancer development and can render cancer cells resistant to anti-cancer treatments.

The gene for Mcl-1 was first discovered in AML cells, but until now it had not been realised that the Mcl-1 protein was critical for AML cells to live, Dr Glaser said. "Other research has already shown that high levels of Mcl-1 are associated with resistance to chemotherapy," said Dr Glaser. "What we have shown is that without Mcl-1, AML cells rapidly die. This is exciting because it identifies Mcl-1 as a potential target for new anti-cancer medications."

Because of the important role pro-survival Bcl-2 family proteins, including Mcl-1, play in cancer development and in the response of cancer cells to treatment, new classes of medications are being developed to block these proteins, making cancer cells die. One class of these medications, called BH3 mimetics, which inhibit certain pro-survival Bcl-2 family proteins, are currently in clinical trials for the treatment of some forms of leukaemia.

Dr Glaser is hopeful that in the future, new treatments for AML will be developed that work by specifically blocking Mcl-1. "We found that many types of AML cells were very dependent on Mcl-1 to survive", he said. "When Mcl-1 was depleted from the AML cells, they rapidly died. Importantly, non-cancerous blood cells were much less susceptible to dying when Mcl-1 was depleted. This means that, if Mcl-1 inhibitors are developed, there may be a 'treatment window' in which AML cells are killed, while normal blood cells that are essential for health can be spared, helping patients recover from the treatment much better. We are optimistic that in the future, Mcl-1 inhibitors may improve the outlook for AML patients, who currently have a very poor prognosis."


'/>"/>

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute
Source:Eurekalert  

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Most maternal deaths in sub-Saharan Africa could be avoided
3. Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case
4. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
5. Hormone thought to slow aging associated with increased risk of cancer death
6. Some Parents Consider Hastening a Sick Childs Death
7. New tool to predict early death or hospital readmission
8. Death After Discharge Rates Higher in Elderly ICU Patients
9. High Hormone Level Linked to Cancer Death in Older Men
10. As Temperatures Rise, So Do Cocaine Deaths
11. PSA Test Reduces Prostate Cancer Deaths by 40%
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cell death researchers identify new Achilles heel in acute myeloid leukemia
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
Breaking Medicine Technology: